From: William Daniels [/O=REGENERON/OU=EXCHANGE ADMINISTRATIVE GROUP

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=WILLIAM.DANIELS]

Sent: Wednesday, February 06, 2013 4:08:00 PM

To: Stephen Dressel
CC: Robert Krukowski
Subject: RE: CDF Donation

Attachments: Regeneron Projections 2013v2.xlsx

Steve,

If you need me to explain again prior to your meeting please call my cell

Bil Daniels, MBA | Senior Manager, Reimbursement Access Programs **REGENERON** Pharmaceuticals, Inc. | 777 Old Saw Mill River Road | Tarrytown, NY 10591 Tel: 914.847.5763 | Fax: 914.593.1154 | Cell: 914.606.0878 | Email: william.daniels@regeneron.com

From: Stephen Dressel

Sent: Wednesday, February 06, 2013 7:40 AM

To: William Daniels

Subject: RE: CDF Donation

Checking with Bob. Can you send me the most recent analysis that you put together? It will need to go to Murray and

Len

Thank you.

Regards, Steve

From: William Daniels

Sent: Tuesday, February 05, 2013 2:08 PM

To: Stephen Dressel **Subject:** CDF Donation **Importance:** High

Steve,

Where are we with this? I have a check request out for 5MM, but I was talking with Rob this am and he was saying we might cancel and just send 15MM?

Bil Daniels, MBA | Senior Manager, Reimbursement Access Programs **REGENERON** Pharmaceuticals, Inc. | 777 Old Saw Mill River Road | Tarrytown, NY 10591 Tel: 914.847.5763 | Fax: 914.593.1154 | Cell: 914.606.0878 | Email: william.daniels@regeneron.com

CONFIDENTIAL REG_000165948

Chronic Disease Fund Request & Rationale

CDF DTPA 2012 91%

AMD Cancellation Rate 20%

Projected Growth Rate by Disease

MD

Total New Patient Funding Needed \$ 19,542,857

Total Existing \$ 14,498,462

0%

Total Projected Funding Needed \$ 34,041,319

	Rollover Patients	Projected New Patients by Quarter 2013							
	Estimated Renewals		1st		2nd		3rd		4th
Age Related Macular Degeneration Patients	6,200		2,500		2,500		2,400		2,100
AMD 1 -Projected Funding Per Patient	\$ 2,250	\$	2,250	\$	2,250	\$	2,250	\$	2,250
AMD 2 -Projected Funding Per Patient	\$ 2,750	\$	2,750	\$	2,750	\$	2,750	\$	2,750
Projected Funding By Quarter	\$ 18,123,077	\$	6,428,571	\$	6,428,571	\$	6,171,429	\$	5,400,000
Cancellation	\$ 3,624,615	\$	1,285,714	\$	1,285,714	\$	1,234,286	\$	1,080,000
Projected Funding Needed By Quarter		\$	5,142,857	\$	5,142,857	\$	4,937,143	\$	4,320,000
Projected CY Funding	\$ 18,123,077	\$	24,428,571						
Projected CY Funding Minus Cancellations	\$ 14,498,462	\$	19,542,857						

Regeneron Modified Estimate of CDF Need

CDF Quoted Population 30,000 Estimated Market Share 30% Regeneron Patient Share 9,000 Total New Patient Funding Needed
Total Existing
Total Projected Funding Needed
Total Existing
Total Projected Funding Needed
Total Existing
Total Projected Funding Needed
Total Projected Funding Needed
Total Projected Funding Needed

	Rollover Patients
	Estimated Renewals
Age Related Macular Degeneration Patients	6,200
Average copay	\$330
Average rollover cost (4x)	\$1,320
Projected Funding Needed	\$8,993,407
Cancellation	\$1,798,68
Projected Renewal Funding	\$8,993,40
Projected CY Funding Minus Cancellations	\$7,194,72

Regeneron New Patients	New Patients			
Modified Estimate	Modified Estimate			
Age Related Macular Degeneration Patients	9,000			
average copay	\$330			
average rollover cost (6x)	\$1,980			
Projected Funding Needed	\$19,582,418			
Cancellation	\$3,916,484			
Projected Renewal Funding	\$19,582,418			
Projected CY Funding Minus Cancellations	\$15,665,934			